Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality

Journal of Clinical Epidemiology

Volumn 54, Issue 12 SUPPL. 1, 2001, Pages

  Goodkin, K ^a,b   Wilkie, F L ^a   Concha, M ^a   Hinkin, C H ^c   Symes, S ^a   Baldewicz, T T ^d   Asthana, D ^a   Fujimura, R K ^a   Lee, D ^a   Van Zuilen, M H ^a,b   Khamis, I ^a   Shapshak, P ^a   Eisdorfer, C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Department of Biology   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PharmaResearch Corporation   (United States)

Author keywords

Aging; HIV 1 associated morbidity; Mortality; Neuro AIDS conditions

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; AMITRIPTYLINE; ANALGESIC AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; OPIATE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; BRAIN LYMPHOMA; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONFERENCE PAPER; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGEVITY; MALE; MORTALITY; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK FACTOR; SURVIVAL TIME; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGE FACTORS; CENTRAL NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBROVASCULAR ACCIDENT; COGNITION DISORDERS; DISEASE PROGRESSION; HIV-1; HUMANS; INCIDENCE; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEUROMUSCULAR DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS; UNITED STATES;

EID: 0035660282     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(01)00445-0     Document Type: Conference Paper

References (89)

1. Influences of age, viral load and CD4+ count on the rate of progression of HIV-1 infection to AIDS
2. Quantifying proviral DNA using the polymerase chain reaction on cerebrospinal fluid and blood of seropositive individuals with and without neurologic abnormalities
3. Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities
4. Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid of children
5. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain
6. HIV-1 RNA levels in cerebrospinal fluid and plasma correlate with AIDS dementia
7. Neurocognitive impairment is an independent risk factor for death in HIV infection
8. Measuring the 'viral load' in cerebrospinal fluid in human immunodeficiency virus infection; window into brain infection?
9. HIV infection and dementia
10. HIV-associated dementia
11. Successful immunosenescence and the remodelling of immune responses with ageing
12. Association of lack of mitogen-induced lymphocyte proliferation with increased mortality in the elderly
13. The HNRC 500- Neuropsychology of HIV infection at different disease stages
14. Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection
15. Cognition in early human immunodeficiency virus infection
16. Rate of CD4 decline and neuropsychological performance in HIV-1 infection
17. Qualitative features of the memory deficit associated with HIV infection and AIDS; cross validation of a discriminant function classification scheme
18. Neuropsychological performance in HIV-1 infected homosexual men; the Multicenter AIDS Cohort Study (MACS)
19. Verbal memory performance of patients with human immunodeficiency virus infection; evidence of subcortical dysfunction
20. The metabolic pathway of the AIDS dementia complex
21. Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus Type-1 (HIV-1) infection
22. Kieburtz K, Epstein L, Marder KS, for the Dana Consortium on the Therapy of HIV-Dementia and Related Cognitive Disorders. Factors associated with incident human immunodeficiency virus-dementia
23. The AIDS dementia complex
24. Neuropsychological studies of asymptomatic human immunodeficiency virus-Type 1 infected individuals
25. Neurological and neuropsychological manifestations of HIV-1 infection; association with AIDS-related complex but not asymptomatic HIV-1 infection
26. The AIDS dementia complex
27. Social support needs of older minority HIV-affected caregivers
28. The dementias of Alzheimer's and AIDS
29. Epidemiology of human immunodeficiency virus encephalopathy in the United States
30. Epidemiology and AIDS dementia complex in Europe
31. Frontal-subcortical features of normal aging; an empirical analysis
32. The cognitive effects of HIV-1 infection in elderly men
33. Cognitive functioning in older individuals with normal aging, HIV-1 infection, and Alzheimer's disease
34. Age differences and neurocognitive performance in HIV-infected adults
35. The relationship between age and cognitive impairment in HIV-1 infection; findings from the Multicenter AIDS Cohort Study and clinical cohort
36. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection; relationship to clinical and neurologic status
37. Independent evolution of HIV type 1 in different brain regions
38. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy
39. Intracerebral cytokine mRNA expression in AIDS dementia
40. The predominant role of IFN-γ in the neuropathogenesis of HIV-1 infection
41. Adherence in AIDS clinical trials; a framework for clinical research and clinical care
42. Dementia in AIDS patients; incidence and risk factors
43. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment
44. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
45. Mild cognitive impairment and risk of mortality in HIV-1 infection
46. Neurological complications of acquired immune deficiency syndrome; analysis of 50 patients
47. HIV-1 associated neuropathies
48. HIV-1 peripheral neuropathy and combination antiretroviral therapy
49. Meta-analysis and the need for study quality control
50. Meta-analysis; a time for closer scrutiny in applications to pain research? Pain forum
51. McKendall R, Singer E, Dal Pan GJ, Clifford DB, Tucker T, Cohen B. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection
52. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291
53. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine
54. Neuromuscular function in HIV infection; analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Trial Group 175-801 Study Team
55. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy; a 5-year cohort study
56. The age-dependent deterioration in light touch sensation on the plantar aspect of the foot in a rural community in India; implication when screening for sensory impairment
57. Plasma viral load and CD4 lymphocytes predict HIV-associated peripheral neuropathy
58. Peripheral neuropathy; a true risk factor for falls
59. PML in 47 HIV-1+ patients
60. In vivo magnetic resonance spectroscopy in HIV and HIV-related brain diseases
61. JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients; predictive value for progressive multifocal leukoencephalopathy
62. Progressive multifocal leukoencephalopathy; the evolution of a disease once considered rare
63. Tumor pathogenesis of human neurotropic JC virus in the CNS
64. HAART improves prognosis in HIV-1-associated progressive multifocal leukoencephalopathy
65. Papovavirus detection by electron microscopy in the brain of an elderly patient without overt progressive multifocal leukoencephalopathy
66. Update on the management of primary CNS lymphoma
67. Is primary CNS lymphoma really becoming more common? A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996
68. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy
69. Human immunodeficiency virus-related lymphoma-prognostic factors predictive of survival
70. AIDS-related brain lesions in the era of highly active antiretroviral therapy
71. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy
72. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL)
73. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-1-infected patients
74. Primary central nervous system lymphoma
75. Performance status and age as independent predictors of survival among AIDS patients with primary CNS lymphoma; a multivariate analysis of a multi-institutional experience
76. Long-term survival in primary CNS lymphoma
77. Central nervous system opportunistic infections in HIV-1 infection
78. HIV associated lymphomas
79. Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma
80. Cerebrovascular disease in AIDS; a case control study
81. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus; a cohort study
82. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
83. Severe premature coronary artery disease with protease inhibitors
84. Cerebrovascular disease in young HIV infected black Africans in the KwaZulu Natal Province of South Africa
85. Cerebral infarction in adult AIDS patients; observations from the Edinburgh HIV Autopsy Cohort
86. Cerebral vasculopathy in HIV infection revealed by transcranial Doppler. A pilot study